BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
BLLN Stock Chart & Stats
$77.00
--
Market closed
$77.00
--
Day’s Range― - ―
52-Week Range$61.96 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)314.76K
Market Cap
$3.20B
Enterprise Value$2.81B
Total Cash (Recent Filing)$495.98M
Total Debt (Recent Filing)$108.89M
Price to Earnings (P/E)502.9
Beta0.26
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding41,413,162
10 Day Avg. Volume246,197
30 Day Avg. Volume314,763
Financial Highlights & Ratios
PEG Ratio-4.71
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue9.21
Enterprise Value/Gross Profit13.48
Enterprise Value/Ebitda152.89
Forecast
1Y Price Target
$120.00Price Target Upside55.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.47
Revenue Forecast (FY)$436.72M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth And Strong GuidanceSustained high single- to triple-digit growth and raised guidance reflect strong product-market fit and scalable commercial execution. Durable demand, rising test volumes and higher ASPs support a multi-quarter revenue runway, improving resource allocation for sales, R&D and system integrations that reinforce long-term topline expansion.
Material Gross Margin ExpansionA substantial and persistent gross margin improvement indicates better unit economics from higher ASPs and lower cost-per-test. Higher gross margins create sustainable operating leverage, allow reinvestment in growth and R&D, and provide a buffer against future price or mix pressure, supporting durable profitability.
Stronger Balance Sheet And De‑leveragingRapid de‑leveraging and a larger equity base materially reduce financial risk and increase flexibility. A healthier capital structure supports investments in commercialization and technology, lowers refinancing risk, and provides optionality for partnerships or tuck-in M&A as the business scales across prenatal and oncology markets.
Bears Say
Negative Mix Shift Toward OncologyRapid oncology growth is positive for revenue but it is lower-margin than prenatal testing; if oncology's share keeps rising, aggregate margins could erode. This structural mix risk forces management to either improve oncology unit economics or accept lower consolidated margins despite higher revenue scale.
Volatile Cash Flow And Conversion UncertaintyWhile cash generation turned positive, large year-to-year swings and inconsistent cash-to-earnings metrics reduce confidence in predictable free cash flow. Persistent volatility can constrain reinvestment, complicate multi‑year planning, and increase sensitivity to execution misses during rapid scaling phases.
Dependence On Reimbursement And EMR IntegrationScaling into large health systems and oncology markets requires costly EMR integrations and expanded payer coverage. These are structural execution hurdles: delays or limited reimbursement restrict adoption, pressure unit economics, and may force extra commercial spend or slower rollout timelines, tempering long-term growth visibility.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $3.20B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 260 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on Mar 04, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.05.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,413,162 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.11 in its last earnings report, beating expectations of $0.06. Following the earnings report the stock price went down -10.714%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$120.00 (55.84% Upside)
$120.00 (55.84% Upside)
Blogger Sentiment
Bullish
BLLN Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.3%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
1.30%
Trailing 12-Months
Asset Growth
109.45%
Trailing 12-Months
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
BillionToOne's first earnings call as a public company highlighted strong revenue growth, successful IPO, and robust gross margins. Despite challenges such as negative mix shifts and the need for further investment in EMR, the company's significant achievements and strong market position reflect a positive outlook.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$120.00
▲(55.84% Upside)
Ownership Overview
34.60% Insiders
4.63%
Mutual Funds
12.09% Other Institutional Investors
47.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---